All In Biotech

Drug Trial Radar · NCT04208412

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

A Randomized, Double-blind, Placebo-controlled, Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Jul 2, 2019

Primary completion

Dec 8, 2020

Study completion Dec 8, 2020

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Dec 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.

Conditions

  • Hereditary Angioedema

Interventions

  • KVD900Drug

    KVD900 tablet 600 mg

  • PlaceboOther

    KVD900-matched Placebo Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug (Full Analysis Set)Time frame: 12 hours

Locations

25 sites in 10 countries. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Scottsdale, Arizona

  • KalVista Investigative Site

    Centennial, Colorado

  • KalVista Investigative Site

    Chevy Chase, Maryland

  • KalVista Investigative Site

    Cincinnati, Ohio

  • KalVista Investigative Site

    Dallas, Texas

  • KalVista Investigative Site

    Spokane, Washington

  • KalVista Investigative Site

    Vienna, Austria

  • KalVista Investigative Site

    Brno, Czechia

  • KalVista Investigative Site

    Hradec Králové, Czechia

  • KalVista Investigative Site

    Pilsen, Czechia

  • KalVista Investigative Site

    Berlin, Germany

  • KalVista Investigative Site

    Frankfurt, Germany

  • KalVista Investigative Site

    Mörfelden-Walldorf, Germany

  • KalVista Investigative Site

    Budapest, Hungary

  • KalVista Investigative Site

    Milan, Italy

  • KalVista Investigative Site

    Milano-2, Italy

  • KalVista Investigative Site

    Padova, Italy

  • KalVista Investigative Site

    Amsterdam, Netherlands

  • KalVista Investigative Site

    Skopje, North Macedonia

  • KalVista Investigative Site

    Krakow, Poland

  • KalVista Investigative Site

    Warsaw, Poland

  • KalVista Investigative Site

    Camberley, United Kingdom

  • KalVista Investigative Site

    Cambridge, United Kingdom

  • KalVista Investigative Site

    London, United Kingdom

  • KalVista Investigative Site

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.